Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27


Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.


Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.


The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4.


Biofeedback in medicine: who, when, why and how?

Frank DL, Khorshid L, Kiffer JF, Moravec CS, McKee MG.

Ment Health Fam Med. 2010 Jun;7(2):85-91.


Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.


Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group.

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.


Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.


Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.


RE: F Schwarz et al.- are single fractions of radiotherapy suitable for plantar fasciitis?

Kiffer J, Lynch R, Francis M, Porter I.

Australas Radiol. 2004 Dec;48(4):529-30. No abstract available.


Plantar fasciitis and the need for translational clarification: in regard to Micke et al. (Int J Radiat Oncol Biol Phys 2004;58: 828-843).

Kiffer J.

Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1338; author reply 1338-9. No abstract available.


Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel.

Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID.

ANZ J Surg. 2004 Aug;74(8):704-5.


Cutaneous basal cell carcinoma of the back metastasizing to the ipsilateral latissimus dorsi muscle.

Kiffer JD, Morris HG.

Clin Oncol (R Coll Radiol). 2003 May;15(3):136-8.


Impact of oedema on implant geometry and dosimetry for temporary high dose rate brachytherapy of the prostate.

Kiffer JD, Schumer WA, Mantle CA, McKenzie BJ, Feigen M, Quong GG, Waterman FM.

Australas Radiol. 2003 Jun;47(2):172-6.


Human milk fatty acids and growth of infants in Brazzaville (The Congo) and Ouagadougou (Burkina Faso).

Rocquelin G, Tapsoba S, Kiffer J, Eymard-Duvernay S.

Public Health Nutr. 2003 May;6(3):241-8.


John Martin Bradley (1925-2000).

Kiffer J, Adler G.

Australas Radiol. 2002 Mar;46(1):132-4. No abstract available.


Reply to: projected requirements for radiation oncologists and trainees in Australia and New Zealand to 2007: reply.

Kiffer JD.

Australas Radiol. 2001 Feb;45(1):104-5. No abstract available.


High proportions of n-6 polyunsaturated fatty acids in mature milk of mothers in Ouagadougou, Burkina Faso.

Rocquelin G, Kiffer J, Tapsoba S, Bouda C.

Acta Paediatr. 2001 Apr;90(4):450-2.


Projected requirements for radiation oncologists and trainees in Australia and New Zealand to 2007: comment.

Kiffer JD.

Australas Radiol. 2000 Aug;44(3):357-9. No abstract available.


Leiomyosarcoma of the rectum: what role does adjuvant therapy play?

Kiffer JD, Castles L, Quong GG, Feigen M.

Australas Radiol. 1999 May;43(2):262-5.


Primary malignant mediastinal germ cell tumours: a literature review and a study of 18 cases.

Kiffer JD, Sandeman TF.

Australas Radiol. 1999 Feb;43(1):58-68. Review.


Supplemental Content

Loading ...
Support Center